Slowing COVID-19 Sales Will Drag On Roche In 2022
Growth To Be Flat Or Low Single Digit
Executive Summary
Strong sales of COVID-19 diagnostics and therapies helped the Swiss company ride out the biosimilar attack in 2021, but it will not have the same buffer this year.
You may also be interested in...
Europe’s Big Pharma Players Begin Tricky 2022 In Style
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.
Readouts For TIGIT And Alzheimer’s Drugs Will Define Roche’s Year
Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.
Roche Has Eylea In Its Sights After Farcimab Approval
Roche’s bispecific antibody, to be called Vabysmo, has got US approval for wet age-related macular degeneration and diabetic macular edema, markets where Bayer and Regeneron's Eylea is a huge seller. The Swiss company hopes that its less-frequent dosing advantage and a price that offers savings over time will make an impact on the market.